In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Millendo Therapeutics Inc.

www.millendo.com

Latest From Millendo Therapeutics Inc.

Alizé Pharma 3 Raises €67m To Build ‘Fully Fledged’ Biotech

The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.

Financing StartUps and SMEs

Start-Up Spruce Repurposes Lilly Drug For Genetic Adrenal Condition

Emerging Company Profile: Spruce and Neurocrine are both testing CRF-R1 antagonists for the orphan disease congenital adrenal hyperplasia, with Phase II data coming soon.

StartUps and SMEs Business Strategies

Venture Funding Deals: Relay Closes Out 2018 With $400m Series C

2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more... 

Deals Financing

Deal Watch: Millendo Completes Merger With OvaScience, With $85m In Bank For Two Mid-Stage Programs

OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Alias(es)
  • Atterocor Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Millendo Therapeutics Inc.
  • Senior Management
  • Julia C Owens, PhD, Pres. & CEO
    Louis Arcudi III, CFO
    Thomas Hoover, VP, Commercial Strategy
    Andrew G Spencer, PhD, VP, Preclinical R&D
    Ryan Zeidan, Chief Dev. Officer
  • Contact Info
  • Millendo Therapeutics Inc.
    Phone: (734) 845-9000
    301 N. Main St., Ste. 100
    Ann Arbor, MI 48104
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register